Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
HOME > ORGANIZATION
ORGANIZATION
- Generic Industry Will Need Strategies Beyond Core Business for “Post-80%” Era: JGA President
January 23, 2020
- Revoke Conditional OK for Stemirac: Drug Damage Watchdog
January 23, 2020
- Japanese Pharma CEOs Gearing Up for New Endeavors in 2020, Fret Scope of Off-Year Re-Pricing
January 9, 2020
- As Off-Year Re-Pricing Looms, JPMA Chief Prods Govt to Minimize Product Coverage
January 7, 2020
- Generic Use Rate at 76.9% in July-September: JGA
December 27, 2019
- Boehringer’s Thorsten Poehl Named as New EFPIA Japan Chief
December 24, 2019
- Industry Leaders Issue Statements on FY2020 Reform Package; Improved PMP Criteria Given Certain Credit
December 23, 2019
- With PMD Law Amended, Japan Pharma Industry Revs Up Work for Electronic Distribution of Prescribing Info
December 5, 2019
- Generic Association to Present Policy Proposal for Govt’s 2020 Honebuto Policy
November 20, 2019
- RIKEN Develops Supercomputer for Molecular Dynamics Simulation, Will Be Made Available to Drug Makers for Drug Discovery Use
November 19, 2019
- JPWA Compares Traceability Regulations to Prevent Distribution of Counterfeit Drugs in Japan, US, EU
November 13, 2019
- JMA Chides MHLW for Information Provisioning on Cefazolin Shortage
October 18, 2019
- Obituary: Harrison Cook, Eli Lilly
October 15, 2019
- Japan Pharmacist Group Taps Ex-Bureaucrat Isobe for Director Post
October 11, 2019
- Patients Want Access to Innovative Drugs Even If Expensive: PhRMA Survey
October 7, 2019
- PhRMA Chair Urges Japan to Rectify PMP Criteria, Narrow Definition of Innovation
October 4, 2019
- Japan Doctors’ Group to Issue Statement to Push for HPV Vaccines by FY2019-End
October 3, 2019
- Generic Industry Pondering Specific Proposal to Address Unreasonable Price Rises
October 2, 2019
- Generic Association Focuses on Pre-symptomatic/Preventive Care and Overseas Expansion in “Post-80% Era”
October 2, 2019
- Generic Use Rate at 75.8% in April-June: JGA
September 27, 2019
ページ
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Combined sales of eight major Japanese drug makers grew nearly 26% year on year in April-September, pushed up by the acquisition of Shire by Takeda Pharmaceutical. Even excluding the industry leader, though, seven firms still collectively eked out a slight…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Indian generic maker Lupin is casting off Kyowa Pharmaceutical Industry, which it acquired in 2007. Forking over 57.4 billion yen…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
While the digital transformation may only be in its infancy in the pharmaceutical industry, the winds of change are here. It’s only a matter of time until customers and patients demand a higher level of service, experience, and connectivity from…